New Frontiers and Treatment Advances for Metastatic Enteropancreatic Neuroendocrine Tumors

02/10/2015 - 02/10/2017

Edward M. Wolin, MD and Pamela L. Kunz, MD, Program Co-Chairs; CME Released 02/10/2015; Valid for credit through 02/10/2017                

Upon completion of this activity, participants will be able to:

  • Detail the epidemiology, burden, and clinical challenges associated with detecting, diagnosing and classifying gastroenteropancreatic neuroendocrine tumors (GEP-NETs);
  • Be more clinically proficient at managing metastatic GEP-NETs at the front lines of oncology practice;
  • Determine which patients with metastatic GEP-NET are appropriate for surgical interventions (resection), medical therapy, systemic chemotherapy, and peptide receptor-targeted radiotherapy, based on presentation, symptoms, tumor types and stage, clinical profiles, extent of disease, biomarkers, and other factors;
  • Identify, assess, and deploy evidence-based treatments for metastatic GEP-NETs based on such outcomes and factors a prolongation of PFS, convenience, patient toleration, and long-term clinical results based on landmark trials and clinical registries;
  • Deploy emerging pharmacologic treatments for patients with GEP-NETs, including somatostatin analogs (SSAs), radiolabeled SSAs, cytotoxic drugs, angiogenesis inhibitors, and mammalian target of rapamycin (mTOR) inhibitors in patients with metastatic GEP-NETs

CME, Drs. Edward Wolin & Pamela Kunz

Print Friendly, PDF & Email